NASAL VACCINE
- January 24, 2021
- Posted by: OptimizeIAS Team
- Category: DPN Topics
No Comments
NASAL VACCINE
Subject: Science & tech
Context: Recently, the Central Drugs Standard Control Organisation recommended granting permission for phase 1 human clinical trials for Bharat Biotech’s nasal COVID-19 vaccine, BBV154.
Concept:
About the Vaccine
- Bharat Biotech has partnered with Washington University School of Medicine in St Louis for a novel intranasal coronavirus vaccine (BBV154).
- Intranasal vaccines are vaccines that are administered through the nose to the mucosal layer.
- An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.
- Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19.
- So far, intranasal vaccination is being used only for influenza.
- However, it cannot be used on certain groups of people, particularly those who have compromised immune systems.
Vaccine Advantages
- The nasal route has excellent potential for vaccination due to the organized immune systems of the nasal mucosa.
- Non-invasive, Needle-free.
- Single dose regimen.
- Ease of administration – does not require trained health care workers.
- Elimination of needle-associated risks (injuries and infections).
- High compliance (Ideally suits for children’s and adults).
- Scalable manufacturing – able to meet global demand.